Cargando…

Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment

Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors predominate as first-line therapy options for renal cell carcinoma. When first-line TKI therapy fails due to resistance development, an optimal second-line therapy has not yet been established. The present investigation is directed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Juengel, Eva, Schnalke, Pascal, Rutz, Jochen, Maxeiner, Sebastian, Chun, Felix K.-H., Blaheta, Roman A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615644/
https://www.ncbi.nlm.nih.gov/pubmed/34829859
http://dx.doi.org/10.3390/biomedicines9111630
_version_ 1784604154133479424
author Juengel, Eva
Schnalke, Pascal
Rutz, Jochen
Maxeiner, Sebastian
Chun, Felix K.-H.
Blaheta, Roman A.
author_facet Juengel, Eva
Schnalke, Pascal
Rutz, Jochen
Maxeiner, Sebastian
Chun, Felix K.-H.
Blaheta, Roman A.
author_sort Juengel, Eva
collection PubMed
description Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors predominate as first-line therapy options for renal cell carcinoma. When first-line TKI therapy fails due to resistance development, an optimal second-line therapy has not yet been established. The present investigation is directed towards comparing the anti-angiogenic properties of the TKIs, sorafenib and axitinib on human endothelial cells (HUVECs) with acquired resistance towards the TKI sunitinib. HUVECs were driven to resistance by continuously exposing them to sunitinib for six weeks. They were then switched to a 24 h or further six weeks treatment with sorafenib or axitinib. HUVEC growth, as well as angiogenesis (tube formation and scratch wound assay), were evaluated. Cell cycle proteins of the CDK-cyclin axis (CDK1 and 2, total and phosphorylated, cyclin A and B) and the mTOR pathway (AKT, total and phosphorylated) were also assessed. Axitinib (but not sorafenib) significantly suppressed growth of sunitinib-resistant HUVECs when they were exposed for six weeks. This axinitib-associated growth reduction was accompanied by a cell cycle block at the G0/G1-phase. Both axitinib and sorafenib reduced HUVEC tube length and prevented wound closure (sorafenib > axitinib) when applied to sunitinib-resistant HUVECs for six weeks. Protein analysis revealed diminished phosphorylation of CDK1, CDK2 and pAKT, accompanied by a suppression of cyclin A and B. Both drugs modulated CDK-cyclin and AKT-dependent signaling, associated either with both HUVEC growth and angiogenesis (axitinib) or angiogenesis alone (sorafenib). Axitinib and sorafenib may be equally applicable as second line treatment options, following sunitinib resistance.
format Online
Article
Text
id pubmed-8615644
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86156442021-11-26 Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment Juengel, Eva Schnalke, Pascal Rutz, Jochen Maxeiner, Sebastian Chun, Felix K.-H. Blaheta, Roman A. Biomedicines Article Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors predominate as first-line therapy options for renal cell carcinoma. When first-line TKI therapy fails due to resistance development, an optimal second-line therapy has not yet been established. The present investigation is directed towards comparing the anti-angiogenic properties of the TKIs, sorafenib and axitinib on human endothelial cells (HUVECs) with acquired resistance towards the TKI sunitinib. HUVECs were driven to resistance by continuously exposing them to sunitinib for six weeks. They were then switched to a 24 h or further six weeks treatment with sorafenib or axitinib. HUVEC growth, as well as angiogenesis (tube formation and scratch wound assay), were evaluated. Cell cycle proteins of the CDK-cyclin axis (CDK1 and 2, total and phosphorylated, cyclin A and B) and the mTOR pathway (AKT, total and phosphorylated) were also assessed. Axitinib (but not sorafenib) significantly suppressed growth of sunitinib-resistant HUVECs when they were exposed for six weeks. This axinitib-associated growth reduction was accompanied by a cell cycle block at the G0/G1-phase. Both axitinib and sorafenib reduced HUVEC tube length and prevented wound closure (sorafenib > axitinib) when applied to sunitinib-resistant HUVECs for six weeks. Protein analysis revealed diminished phosphorylation of CDK1, CDK2 and pAKT, accompanied by a suppression of cyclin A and B. Both drugs modulated CDK-cyclin and AKT-dependent signaling, associated either with both HUVEC growth and angiogenesis (axitinib) or angiogenesis alone (sorafenib). Axitinib and sorafenib may be equally applicable as second line treatment options, following sunitinib resistance. MDPI 2021-11-06 /pmc/articles/PMC8615644/ /pubmed/34829859 http://dx.doi.org/10.3390/biomedicines9111630 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Juengel, Eva
Schnalke, Pascal
Rutz, Jochen
Maxeiner, Sebastian
Chun, Felix K.-H.
Blaheta, Roman A.
Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
title Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
title_full Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
title_fullStr Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
title_full_unstemmed Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
title_short Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
title_sort antiangiogenic properties of axitinib versus sorafenib following sunitinib resistance in human endothelial cells—a view towards second line renal cell carcinoma treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615644/
https://www.ncbi.nlm.nih.gov/pubmed/34829859
http://dx.doi.org/10.3390/biomedicines9111630
work_keys_str_mv AT juengeleva antiangiogenicpropertiesofaxitinibversussorafenibfollowingsunitinibresistanceinhumanendothelialcellsaviewtowardssecondlinerenalcellcarcinomatreatment
AT schnalkepascal antiangiogenicpropertiesofaxitinibversussorafenibfollowingsunitinibresistanceinhumanendothelialcellsaviewtowardssecondlinerenalcellcarcinomatreatment
AT rutzjochen antiangiogenicpropertiesofaxitinibversussorafenibfollowingsunitinibresistanceinhumanendothelialcellsaviewtowardssecondlinerenalcellcarcinomatreatment
AT maxeinersebastian antiangiogenicpropertiesofaxitinibversussorafenibfollowingsunitinibresistanceinhumanendothelialcellsaviewtowardssecondlinerenalcellcarcinomatreatment
AT chunfelixkh antiangiogenicpropertiesofaxitinibversussorafenibfollowingsunitinibresistanceinhumanendothelialcellsaviewtowardssecondlinerenalcellcarcinomatreatment
AT blahetaromana antiangiogenicpropertiesofaxitinibversussorafenibfollowingsunitinibresistanceinhumanendothelialcellsaviewtowardssecondlinerenalcellcarcinomatreatment